

1032

PTO/SB/21 (08-03)

Approved for use through 08/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/903,393
	Filing Date	July 10, 2001
	First Named Inventor	Keith D. Allen
	Art Unit	1632
	Examiner Name	Ram R. Shukla
Total Number of Pages in This Submission	Attorney Docket Number	R-387

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Kelly L. Quast, Reg. No. 52,141	
Signature		
Date	September 17, 2003	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Don Mixon	
Signature		Date September 17, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Keith D. ALLEN

Serial No.: 09/903,393

Filed: July 10, 2001

Title: Transgenic Mice Containing Limulus
Clotting Factor Protease-Like Gene
Disruptions

Group Art Unit: 1632

Examiner: Shukla, Ram R.

Customer No. 26619

Docket/Order No. R-387

Date: September 17, 2003

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Mail Stop Non-Fee Amendments
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed August 19, 2003 concerning the Examiner's restriction to the claims in connection with the above-referenced application, Applicants elect without traverse Group III (claims 8-12, 15 and 17-24), drawn to a transgenic mouse comprising a disruption in its endogenous limulus clotting factor protease-like gene and a method of screening for agents using the transgenic mouse. It is believed that no fees are due associated with the instant response. However, the Commissioner is hereby authorized to charge any deficiency in payment to Deposit Account No. 50-1271 under Order No. R-387.

Respectfully submitted,


Date: 9/17/03

Kelly L. Quast
Kelly L. Quast, Reg. No. 52,141
Deltagen, Inc.
1031 Bing St.
San Carlos, CA 94070
(650) 569-5100

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence and its listed enclosures is being deposited with the United States Postal Service as First Class Mail, postage paid, in an envelope addressed to: Commissioner for Patents, Alexandria, VA, Mail Stop Non- Fee Amendment/OIPE on **September 17, 2003**.

Name: **Don Mixon**

Signed: 

Date: 9/17/03